Literature DB >> 29359317

Modeling survival distribution as a function of time to treatment discontinuation: A dynamic treatment regime approach.

Shu Yang1, Anastasios A Tsiatis1, Michael Blazing2.   

Abstract

We consider estimating the effect that discontinuing a beneficial treatment will have on the distribution of a time to event clinical outcome, and in particular assessing whether there is a period of time over which the beneficial effect may continue after discontinuation. There are two major challenges. The first is to make a distinction between mandatory discontinuation, where by necessity treatment has to be terminated and optional discontinuation which is decided by the preference of the patient or physician. The innovation in this article is to cast the intervention in the form of a dynamic regime "terminate treatment optionally at time v unless a mandatory treatment-terminating event occurs prior to v" and consider estimating the distribution of time to event as a function of treatment regime v. The second challenge arises from biases associated with the nonrandom assignment of treatment regimes, because, naturally, optional treatment discontinuation is left to the patient and physician, and so time to discontinuation may depend on the patient's disease status. To address this issue, we develop dynamic-regime Marginal Structural Models and use inverse probability of treatment weighting to estimate the impact of time to treatment discontinuation on a time to event outcome, compared to the effect of not discontinuing treatment. We illustrate our methods using the IMPROVE-IT data on cardiovascular disease.
© 2018, The International Biometric Society.

Entities:  

Keywords:  Dynamic treatment; Inverse weighting; Observational study; Survival distribution; Time-varying confounding; Treatment discontinuation

Mesh:

Year:  2018        PMID: 29359317      PMCID: PMC6054909          DOI: 10.1111/biom.12845

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  17 in total

1.  Estimating mean response as a function of treatment duration in an observational study, where duration may be informatively censored.

Authors:  Brent A Johnson; Anastasios A Tsiatis
Journal:  Biometrics       Date:  2004-06       Impact factor: 2.571

2.  A sequential Cox approach for estimating the causal effect of treatment in the presence of time-dependent confounding applied to data from the Swiss HIV Cohort Study.

Authors:  Jon Michael Gran; Kjetil Røysland; Marcel Wolbers; Vanessa Didelez; Jonathan A C Sterne; Bruno Ledergerber; Hansjakob Furrer; Viktor von Wyl; Odd O Aalen
Journal:  Stat Med       Date:  2010-11-20       Impact factor: 2.373

Review 3.  Comparison of dynamic treatment regimes via inverse probability weighting.

Authors:  Miguel A Hernán; Emilie Lanoy; Dominique Costagliola; James M Robins
Journal:  Basic Clin Pharmacol Toxicol       Date:  2006-03       Impact factor: 4.080

4.  Estimation and extrapolation of optimal treatment and testing strategies.

Authors:  James Robins; Liliana Orellana; Andrea Rotnitzky
Journal:  Stat Med       Date:  2008-10-15       Impact factor: 2.373

5.  Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.

Authors:  Christopher P Cannon; Michael A Blazing; Robert P Giugliano; Amy McCagg; Jennifer A White; Pierre Theroux; Harald Darius; Basil S Lewis; Ton Oude Ophuis; J Wouter Jukema; Gaetano M De Ferrari; Witold Ruzyllo; Paul De Lucca; KyungAh Im; Erin A Bohula; Craig Reist; Stephen D Wiviott; Andrew M Tershakovec; Thomas A Musliner; Eugene Braunwald; Robert M Califf
Journal:  N Engl J Med       Date:  2015-06-03       Impact factor: 91.245

6.  Methods for dealing with time-dependent confounding.

Authors:  R M Daniel; S N Cousens; B L De Stavola; M G Kenward; J A C Sterne
Journal:  Stat Med       Date:  2012-12-03       Impact factor: 2.373

7.  A linear regression model for the analysis of life times.

Authors:  O O Aalen
Journal:  Stat Med       Date:  1989-08       Impact factor: 2.373

8.  Semiparametric estimation in a three-state duration-dependent Markov model from interval-censored observations with application to AIDS data.

Authors:  H Frydman
Journal:  Biometrics       Date:  1995-06       Impact factor: 2.571

9.  Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes.

Authors:  Christopher P Cannon; Robert P Giugliano; Michael A Blazing; Robert A Harrington; John L Peterson; Christine McCrary Sisk; John Strony; Thomas A Musliner; Carolyn H McCabe; Enrico Veltri; Eugene Braunwald; Robert M Califf
Journal:  Am Heart J       Date:  2008-09-02       Impact factor: 4.749

10.  Inference on treatment effects from a randomized clinical trial in the presence of premature treatment discontinuation: the SYNERGY trial.

Authors:  Min Zhang; Anastasios A Tsiatis; Marie Davidian; Karen S Pieper; Kenneth W Mahaffey
Journal:  Biostatistics       Date:  2010-08-25       Impact factor: 5.899

View more
  5 in total

1.  Estimating mean potential outcome under adaptive treatment length strategies in continuous time.

Authors:  Hao Sun; Ashkan Ertefaie; Brent A Johnson
Journal:  Biometrics       Date:  2021-06-04       Impact factor: 1.701

2.  Semiparametric estimation of structural nested mean models with irregularly spaced longitudinal observations.

Authors:  Shu Yang
Journal:  Biometrics       Date:  2021-04-29       Impact factor: 1.701

3.  A treatment-specific marginal structural Cox model for the effect of treatment discontinuation.

Authors:  Dana Johnson; Karen Pieper; Shu Yang
Journal:  Pharm Stat       Date:  2022-03-31       Impact factor: 1.234

4.  Risks associated with discontinuation of oral anticoagulation in newly diagnosed patients with atrial fibrillation: Results from the GARFIELD-AF Registry.

Authors:  Frank Cools; Dana Johnson; Alan J Camm; Jean-Pierre Bassand; Freek W A Verheugt; Shu Yang; Anastasios Tsiatis; David A Fitzmaurice; Samuel Z Goldhaber; Gloria Kayani; Shinya Goto; Sylvia Haas; Frank Misselwitz; Alexander G G Turpie; Keith A A Fox; Karen S Pieper; Ajay K Kakkar
Journal:  J Thromb Haemost       Date:  2021-07-23       Impact factor: 5.824

5.  Estimating vaccine efficacy over time after a randomized study is unblinded.

Authors:  Anastasios A Tsiatis; Marie Davidian
Journal:  Biometrics       Date:  2021-08-13       Impact factor: 1.701

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.